November’s US midterm elections swept Democrats into power in both the House and Senate, marking a shift in congressional leadership on key health policies. This comes as a former Trump administration official and a founder of the “Make America Healthy Again” (MAHA) movement accused the administration of catering to industry interests over the health of […] Continue reading ->
WHO has greenlighted Phase 2/3 trials for two brand new vaccine candidates that specifically target the Ebola Bundibugyo virus species ravaging the Democratic Republic of Congo. Actual trials could forseeably commence  “within three to four weeks” – as soon as  DRC regulators issue their own approval,  said WHO’s Science Director Meg Doherty, at a Wednesday […] Continue reading ->
The US Food and Drug Administration (FDA) has approved the first generic version of lenacapavir, the highly effective twice-yearly injection to prevent HIV, developed by Dr Reddy’s Laboratories based in India. Dr Reddy’s was one of six pharmaceutical manufacturers that was granted a non-exclusive, royalty-free voluntary licensing agreement from Gilead, which developed lenacapavir. The agreement, […] Continue reading ->
The Medicines Patent Pool (MPP) has signed sublicense agreements with 11 manufacturers across multiple regions to expand access to generic baloxavir marboxil, a single-dose antiviral treatment for influenza that was originally developed by Swiss pharmaceutical company Roche.  The announcement, made the night before last Friday’s UN High-Level Meeting on Pandemic Prevention, Preparedness and Response, reignited […] Continue reading ->
A new modelling study suggests that US Medicare “Most-Favored-Nation” policies on drug prices would cut Medicare spending on brand-name drugs, but potentially incentivize companies to increase prices or delay new drug launches elsewhere. Efforts to control the cost of government spending on drugs culminated in a Most-Favored-Nation (MFN) policy, a Trump administration initiative which ties […] Continue reading ->